PD Med Collaborative Group, Gray R, Ives N, et al : Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384 : 1196-1205, 2014.
Hauser RA, Li R, Pérez A, et al : Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. J Parkinsons Dis 7 : 117-127, 2017.
Miklya I : The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). Mol Psychiatry 21 : 1499-1503, 2016.
Harsing LG Jr, Magyar K, Tekes K, et al : Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition. Pol J Pharmacol Pharm 31 : 297-307, 1979.